MedTrace Logo

Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine

NCT05706324 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-25

No results posted yet for this study

Summary

In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation, RCVi) at low, medium, and high doses in healthy adults (previously primed with authorized vaccines).

Conditions

Interventions

BIOLOGICAL

Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation

0.2mL/dose, Inhalation using a nebulizer

Sponsors & Collaborators

  • National University Hospital, Singapore

    collaborator OTHER

  • Shanghai BravoBio Co., Ltd.

    collaborator UNKNOWN

  • Wuhan BravoVax Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2023-12-31
Completion
2024-07-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05706324 on ClinicalTrials.gov